^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
Published date:
01/14/2021
Excerpt:
This real-world, multicenter, retrospective, observational study included patients with BRAF V600-mutated mCRC treated in eight hospitals in Spain….Median OS was 11.8 months in patients who received antiangiogenic-based CT compared with 12.4 months in those who did not (hazard ratio [HR], 1.196; 95% CI, 0.7–2.1; p = 0.529) (Fig. 2b).
DOI:
10.1186/s12885-020-07758-5
